



PATIENT INFORMATION	Patient Name: _____	PRESCRIBER INFORMATION	Prescriber's Name: _____
	Address: _____		State License #: _____ NPI #: _____
	City: _____ State: _____ Zip: _____		DEA #: _____
	Primary Phone: _____ DOB: _____		Group or Hospital: _____
	Alternate Phone: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female		Address: _____
	Email: _____		City: _____ State: _____ Zip: _____
	Primary Language: _____		Phone: _____ Fax: _____
	Height: _____ Weight: _____		Contact Person: _____ Phone: _____

INSURANCE INFORMATION: PLEASE FAX A COPY OF THE PRESCRIPTION & INSURANCE CARDS WITH THIS FORM, IF AVAILABLE (FRONT & BACK)

CLINICAL	Need By Date: _____	Ship to: <input type="checkbox"/> Patient <input type="checkbox"/> Physician <input type="checkbox"/> Other:		
	Date of Diagnosis: _____	<input type="checkbox"/> Clinically Isolated Syndrome	<input type="checkbox"/> Relapsing-Remitting	<input type="checkbox"/> Secondary Progressive
	Diagnosis: G35 Multiple Sclerosis	<input type="checkbox"/> Other (ICD-10 Code): _____	<input type="checkbox"/> Primary Progressive	Number of Relapses Last Year: _____
	Previous Disease-Modifying Therapy: _____			
	Current Medications: _____			
Allergies: _____			Is the patient new to therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	

	MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILLS
PRESCRIPTION INFORMATION	<input type="checkbox"/> Aubagio	<input type="checkbox"/> 7mg <input type="checkbox"/> 14mg	<input type="checkbox"/> Take 1 tab PO daily	<input type="checkbox"/> 30	_____
	<input type="checkbox"/> Avonex PFS <input type="checkbox"/> Avonex Pen	<input type="checkbox"/> 30mcg	<input type="checkbox"/> Titration Dosing (PFS): Week 1: Inject 7.5mcg IM Week 2: Inject 15mcg IM Week 3: Inject 22.5mcg IM Week 4: Start injecting 30mcg IM once a week <input type="checkbox"/> Inject 30mcg IM once a week	<input type="checkbox"/> 1 Kit = 4 PFS <input type="checkbox"/> 1 Kit = 4 Pens	_____
	<input type="checkbox"/> Betaseron	<input type="checkbox"/> 0.3mg	<input type="checkbox"/> Titration Dosing: Weeks 1-2: Inject 0.0625mg (0.25mL) SQ QOD Weeks 3-4: Inject 0.125mg (0.5mL) SQ QOD Weeks 5-6: Inject 0.1875mg (0.75mL) SQ QOD Week 7: Start injecting 0.25mg (1mL) SQ QOD <input type="checkbox"/> Inject 0.25mg (1mL) SQ every other day	<input type="checkbox"/> 1 Kit = 14 Devices	_____
	<input type="checkbox"/> Copaxone PFS <input type="checkbox"/> Glatopa PFS <input type="checkbox"/> Glatiramer acetate PFS	<input type="checkbox"/> 20mg <input type="checkbox"/> 40mg	<input type="checkbox"/> Inject 20mg SQ daily <input type="checkbox"/> Inject 40mg SQ 3 times a week <input type="checkbox"/> Other _____	<input type="checkbox"/> 1 Kit = 30 PFS <input type="checkbox"/> 1 Kit = 12 PFS	_____
	<input type="checkbox"/> Dalfampridine	<input type="checkbox"/> 10mg Tab	<input type="checkbox"/> Take 1 tablet PO twice daily approximately 12 hours apart	<input type="checkbox"/> 60	_____
	<input type="checkbox"/> Extavia	<input type="checkbox"/> 0.3mg	<input type="checkbox"/> Titration Dosing: Weeks 1-2: Inject 0.0625mg (0.25mL) SQ QOD Weeks 3-4: Inject 0.125mg (0.5mL) SQ QOD Weeks 5-6: Inject 0.1875mg (0.75mL) SQ QOD Week 7: Start injecting 0.25mg (1mL) SQ QOD <input type="checkbox"/> Inject 0.25mg (1mL) SQ every other day	<input type="checkbox"/> 1 Kit = 15 devices	_____
	<input type="checkbox"/> Gilenya	<input type="checkbox"/> 0.5mg Cap	<input type="checkbox"/> Take 1 cap PO daily	<input type="checkbox"/> 30	_____
	<input type="checkbox"/> Kesimpta Pen	<input type="checkbox"/> 20mg/0.4 mL	<input type="checkbox"/> Initial Dose: Inject 20mg SQ on day 1, day 8, and day 15, followed by 20mg SQ once monthly starting on day 29 <input type="checkbox"/> Inject 20mg SQ once monthly	<input type="checkbox"/> 3 Pens <input type="checkbox"/> 1 Pen	NA _____

PHYSICIAN SIGNATURE REQUIRED

x _____ x _____
DISPENSE AS WRITTEN (Date) PRODUCT SUBSTITUTION PERMITTED (Date)
Ancillary supplies and kits provided as needed for administration

Date Needed: _____ Medication Start Date: _____

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document. 0124 (4/21)

This prescription is valid only if transmitted by facsimile machine by a licensed provider.



PATIENT INFORMATION	Patient Name: _____	PRESCRIBER INFORMATION	Prescriber's Name: _____
	Address: _____		State License #: _____ NPI #: _____
	City: _____ State: _____ Zip: _____		DEA #: _____
	Primary Phone: _____ DOB: _____		Group or Hospital: _____
	Alternate Phone: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female		Address: _____
	Email: _____		City: _____ State: _____ Zip: _____
	Primary Language: _____		Phone: _____ Fax: _____
	Height: _____ Weight: _____		Contact Person: _____ Phone: _____

INSURANCE INFORMATION: PLEASE FAX A COPY OF THE PRESCRIPTION & INSURANCE CARDS WITH THIS FORM, IF AVAILABLE (FRONT & BACK)

CLINICAL	Need By Date: _____	Ship to: <input type="checkbox"/> Patient <input type="checkbox"/> Physician <input type="checkbox"/> Other:	
	Date of Diagnosis: _____	<input type="checkbox"/> Clinically Isolated Syndrome <input type="checkbox"/> Relapsing-Remitting <input type="checkbox"/> Secondary Progressive <input type="checkbox"/> Primary Progressive	Number of Relapses Last Year: _____
	Diagnosis: G35 Multiple Sclerosis	<input type="checkbox"/> Other (ICD-10 Code): _____	
	Previous Disease-Modifying Therapy: _____		
	Current Medications: _____		
Allergies: _____		Is the patient new to therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	

	MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILLS
PRESCRIPTION INFORMATION	<input type="checkbox"/> Mayzent	CYP2C9 Genotype *1/*1, *1/*2, and *2/*2 <input type="checkbox"/> Titration Pack (5-day)	<input type="checkbox"/> Titration Dosing: 0.25mg PO day 1-2, 0.5mg day 3, 0.75mg day 4, 1.25mg day 5, followed by 2mg daily thereafter	<input type="checkbox"/> 1 Titration Kit	NA
		<input type="checkbox"/> 2mg Tab	<input type="checkbox"/> Take 2mg PO daily	<input type="checkbox"/> 30	_____
	<input type="checkbox"/> Ocrevus	<input type="checkbox"/> 300mg/10mL	<input type="checkbox"/> Titration Dosing: 0.25mg PO day 1-2, 0.5mg day 3, 0.75mg day 4, followed by 1mg daily thereafter	<input type="checkbox"/> 112	_____
			<input type="checkbox"/> 0.25mg Tab	<input type="checkbox"/> Take 1mg PO daily	
	<input type="checkbox"/> Plegridy SQ PFS <input type="checkbox"/> Plegridy SQ Autoinjector	<input type="checkbox"/> Titration Pack <input type="checkbox"/> 125mcg/0.5mL	<input type="checkbox"/> Initial Dose: Infuse 300mg IV on day 1, followed by 300mg IV 2 weeks later	<input type="checkbox"/> 2 SDV	_____
			<input type="checkbox"/> Maintenance Dose: Infuse 600mg IV every 6 months		
	<input type="checkbox"/> Plegridy IM PFS	<input type="checkbox"/> 125mcg/0.5mL	<input type="checkbox"/> Titration Dose: Inject 63mcg SQ on day 1, 94mcg on day 15, 125mcg on day 29 and every 14 days thereafter	<input type="checkbox"/> 1 Titration Kit = 2 Pen/PFS	_____
			<input type="checkbox"/> Inject 125mcg SQ every 14 days	<input type="checkbox"/> 2	
	<input type="checkbox"/> Rebif PFS <input type="checkbox"/> Rebif Rebidose Autoinjector	<input type="checkbox"/> Titration Pack	<input type="checkbox"/> Titration to 22mcg dose (PFS only): Weeks 1-2: Inject 4.4mcg SQ 3 times a week Weeks 3-4: Inject 11mcg SQ 3 times a week Week 5: Start injecting 22mcg SQ 3 times a week	<input type="checkbox"/> 1 Titration Kit = six 8.8mcg + six 22mcg syringes or autoinjectors	0
			<input type="checkbox"/> Titration to 44mcg dose: Weeks 1-2: Inject 8.8mcg SQ 3 times a week Weeks 3-4: Inject 22mcg SQ 3 times a week Week 5: Start injecting 44mcg SQ 3 times a week		
<input type="checkbox"/> Rebif PFS <input type="checkbox"/> Rebif Rebidose Autoinjector	<input type="checkbox"/> 22mcg <input type="checkbox"/> 44mcg	<input type="checkbox"/> Inject 22mcg SQ 3 times a week	<input type="checkbox"/> 12	_____	
		<input type="checkbox"/> Inject 44mcg SQ 3 times a week			
		<input type="checkbox"/> Other _____			

PHYSICIAN SIGNATURE REQUIRED

_____ x DISPENSE AS WRITTEN (Date) Ancillary supplies and kits provided as needed for administration	_____ x PRODUCT SUBSTITUTION PERMITTED (Date)
--	--

Date Needed: _____ Medication Start Date: _____

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document. 0124 (4/21)



PATIENT INFORMATION	Patient Name: _____	PRESCRIBER INFORMATION	Prescriber's Name: _____
	Address: _____		State License #: _____ NPI #: _____
	City: _____ State: _____ Zip: _____		DEA #: _____
	Primary Phone: _____ DOB: _____		Group or Hospital: _____
	Alternate Phone: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female		Address: _____
	Email: _____		City: _____ State: _____ Zip: _____
	Primary Language: _____		Phone: _____ Fax: _____
	Height: _____ Weight: _____		Contact Person: _____ Phone: _____

INSURANCE INFORMATION: PLEASE FAX A COPY OF THE PRESCRIPTION & INSURANCE CARDS WITH THIS FORM, IF AVAILABLE (FRONT & BACK)

CLINICAL	Need By Date: _____	Ship to: <input type="checkbox"/> Patient <input type="checkbox"/> Physician <input type="checkbox"/> Other:
	Date of Diagnosis: _____	<input type="checkbox"/> Clinically Isolated Syndrome <input type="checkbox"/> Relapsing-Remitting <input type="checkbox"/> Secondary Progressive <input type="checkbox"/> Primary Progressive
	Diagnosis: G35 Multiple Sclerosis	<input type="checkbox"/> Other (ICD-10 Code): _____
	Previous Disease-Modifying Therapy:	Number of Relapses Last Year: _____
	Current Medications:	
Allergies: _____	Is the patient new to therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	

	MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILLS
PRESCRIPTION INFORMATION	<input type="checkbox"/> Tecfidera <input type="checkbox"/> Dimethyl Fumarate	<input type="checkbox"/> Starter Kit	<input type="checkbox"/> Titration Dose: Take 120mg PO twice daily for 7 days, then take 240mg twice daily thereafter	<input type="checkbox"/> 1 Starter Kit (60 caps)	
		<input type="checkbox"/> 120mg DR Cap (dispensed in multiples of #14)	<input type="checkbox"/> Take 240mg PO twice daily	<input type="checkbox"/> 60	—
		<input type="checkbox"/> 240mg DR Cap	<input type="checkbox"/> Other _____	<input type="checkbox"/> Other _____	
	<input type="checkbox"/> Vumerity	<input type="checkbox"/> 231mg DR Cap	<input type="checkbox"/> Titration Dose: Take 231mg PO twice daily for 7 days, then take 462mg twice daily thereafter	<input type="checkbox"/> 106 Caps (titration)	NA
			<input type="checkbox"/> Take 462mg PO twice daily	<input type="checkbox"/> 120	—
			<input type="checkbox"/> Other _____	<input type="checkbox"/> _____	—
	<input type="checkbox"/> Zeposia	<input type="checkbox"/> Titration Pack (7-day)	<input type="checkbox"/> Titration Dose: 0.23mg PO day 1-4, 0.46mg day 5-7, followed by 0.92mg daily thereafter	<input type="checkbox"/> 1 Titration Kit	NA
		<input type="checkbox"/> Titration Pack (37-day)	<input type="checkbox"/> Take 0.92mg PO daily	<input type="checkbox"/> 30	—
		<input type="checkbox"/> 0.92mg Cap			

PHYSICIAN SIGNATURE REQUIRED

_____ x DISPENSE AS WRITTEN (Date) Ancillary supplies and kits provided as needed for administration	_____ x PRODUCT SUBSTITUTION PERMITTED (Date)
--	--

Date Needed: _____ Medication Start Date: _____

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document. 0124 (4/21)